Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway

Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5239-5246. doi: 10.26355/eurrev_201711_13847.

Abstract

Objective: To observe the effect of metformin on the tight junction of intestinal epithelial cells and its relevant mechanism.

Materials and methods: Caco-2 cell monolayers were incubated with or without tumor necrosis factor-α (TNF-α) (10 ng/mL) in the absence or presence of indicated concentrations of metformin. Transepithelial electrical resistance (TEER) was measured at various time points. Caco-2 cell permeability was assessed using fluorescein permeability test. Immunofluorescence was used to detect the distribution of tight junction protein. Western blotting and Real-Time PCR were used to detect the expression of tight junction protein and Myosin light chain kinase (MLCK)-Myosin light chain (MLC) signaling pathway.

Results: Metformin attenuates the effects of TNF-α on Caco-2 cell TEER and paracellular permeability, prevents TNF-α-induced morphological disruption of tight junctions, ameliorates the inhibiting effect of TNF-α on epithelial tight junction-related protein expression and suppresses the TNF-α-induced increase in MLCK production.

Conclusions: Metformin can stabilize and up-regulate tight junction protein by inhibiting MLCK-MLC signaling pathway, thus ameliorating the tight junction of intestinal epithelial cells.

MeSH terms

  • Caco-2 Cells
  • Cell Membrane / drug effects
  • Epithelial Cells / drug effects*
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Intestinal Mucosa / cytology
  • Intestinal Mucosa / drug effects*
  • Metformin / pharmacology*
  • Myosin Light Chains / drug effects*
  • Myosin-Light-Chain Kinase / drug effects*
  • Signal Transduction / drug effects
  • Tight Junction Proteins / biosynthesis
  • Tight Junction Proteins / drug effects
  • Tight Junctions / drug effects*
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Hypoglycemic Agents
  • Myosin Light Chains
  • Tight Junction Proteins
  • Tumor Necrosis Factor-alpha
  • Metformin
  • Myosin-Light-Chain Kinase